Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases

Published: Thursday, April 17, 2014
Last Updated: Thursday, April 17, 2014
Bookmark and Share
Company’s IKKe/TBK1 programme to offer a disease-modifying treatment for COPD patients.

Domainex Ltd. has announced that it has successfully completed a series of laboratory studies examining the in vivo effects of its proprietary selective inhibitors of IKK-epsilon and TBK1 in inflammation models.

In four separate studies a lipopolysaccharide (LPS) challenge was delivered either to the lungs or systemically to mimic the effect of inflammatory disease.

In these experiments Domainex showed that its orally-delivered compounds can inhibit the expression of a number of pro-inflammatory cytokines including TNF-alpha, RANTES, IL-1-beta, and IL-6, and maintain prolonged activity against many of the cytokines for at least 20 hours.

No side-effects were evident in these studies. These results are extremely promising in the search for new treatments of life-limiting diseases such as chronic obstructive pulmonary disease (COPD).

Domainex’s IKKe/TBK1 programme is first-in-class, and promises to offer a disease-modifying treatment for COPD patients, whereas existing treatments merely provide them with symptomatic relief.

Domainex’s Director of Research, Dr Trevor Perrior said: “These exciting results clearly show that Domainex’s programme on IKKe/TBK1 offers the prospect of new treatments for a number of inflammatory diseases, including psoriasis, rheumatoid arthritis and COPD. It’s also very significant that the compounds can be delivered orally, because in many of these diseases - such as psoriasis and COPD - patients are in great need of effective oral medicines”.

Domainex’s CEO Dr Eddy Littler said: “This is a major achievement by Domainex and we will build upon this success with further in vivo models of inflammatory diseases. Our first disease model will be for COPD, a disease which has high medical need and enormous commercial potential. Our compounds are likely to achieve the highly-attractive profile of being safe, effective, and orally-delivered anti-inflammatory compounds”.

Domainex will continue to study the utility of these compounds as treatments for COPD, and other inflammatory diseases. It hopes to partner the programme soon and to proceed to Phase I Clinical Trials.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ZoBio, Domainex Partner to support FORMA Therapeutics’ Drug Discovery Programs
ZoBio and Domainex Ltd. announce a collaboration with FORMA Therapeutics to provide NMR-based structural biology services for a substantial panel of FORMA drug targets.
Monday, December 08, 2014
Auspherix and Domainex Announce Collaboration
Collaboration to develop new drugs to treat antibiotic-resistant bacterial infections.
Wednesday, October 15, 2014
University of Warwick Wins Domainex’s First Discovery STAR Award
Domainex Ltd. has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick.
Monday, September 02, 2013
Domainex Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling
Inhibitors may have utility in autoimmune disease treatment.
Monday, November 05, 2012
Domainex Awarded Technology Strategy Board Funding
£250,000 grant to support the development of a new drug for the treatment of cancers.
Friday, November 04, 2011
Domainex Wins Genesis Award for its Work in Supporting Translational Research
Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award.
Wednesday, December 15, 2010
Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins
Under the collaboration, Domainex uses CDH technology, which enables researchers to clone and express challenging proteins, to produce soluble domains of a number of proteins that have key roles in epigenetics.
Tuesday, November 16, 2010
Domainex Lead Optimization Services Facilitate a new Cancer Drug Discovery Programme
The Company is now set to provide lead optimization services in collaboration with The Institute of Cancer Research.
Thursday, April 08, 2010
Domainex Collaborates with St George’s University and The University of Manchester for Asthma Treatment
The £1.5 million collaboration focuses on a new drug discovery programme to provide a better treatment for asthma.
Friday, July 10, 2009
Domainex and Ark Therapeutics Extend Drug Discovery Agreement
Domainex continues providing Ark with hit-finding and lead optimization services for drug discovery against exciting therapeutic targets.
Thursday, July 09, 2009
Domainex Ltd Wins Biotechnology Innovation Award
The award was presented by UK Trade & Investment for developing new technologies for streamlining and accelerating the drug discovery process.
Wednesday, August 22, 2007
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!